Results 131 to 140 of about 1,455 (196)

Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome. [PDF]

Nature
Narendra VK, Das T, Wierciszewski LJ, Londoner RJ, Morrison JK, Martindale P, Devine T, Chen K, Trombetta M, Kanno Y, Casiano AE, de Stanchina E, Lareau CA, Lowe SW, Gitlin AD.   +14 more
europepmc   +1 more source

VEXAS syndrome-associated tumefactive demyelination. [PDF]

J Neurol
Eatz T, Gultekin SH, Chandhok NS, O'Phelan KH, Koch S.   +4 more
europepmc   +1 more source

Case Report: Early-onset VEXAS syndrome with recurrent pulmonary inflammation and myelodysplasia: a diagnostic and therapeutic challenge. [PDF]

Front Immunol
Jin X, Jiang X, Liu Y, Chen M, Dai J, Xu J, Shen M.   +6 more
europepmc   +1 more source

Extensive reactive cutaneous histiocytic infiltrate resembling non-Langerhans cell histiocytosis as the presenting sign of underlying vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome [PDF]

Musiek, Amy C, Rosman, Ilana S, Wang, Cynthia X, Yokoyama, Christine C   +3 more
core   +2 more sources

VEXAS syndrome in rheumatology practice: features from a multicenter cohort in north-east Italy. [PDF]

Front Immunol
Bindoli S, Morello-Pasin G, Guidea I, Padoan R, Iorio L, Bixio R, Orsolini G, Maiolini F, Lombardi S, Lombardi S, Favero M, Bernardi C, Raffeiner B, Doria A, Ramonda R, Sfriso P.   +15 more
europepmc   +1 more source

Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome. [PDF]

Am J Clin Pathol
Wadsworth PA, Chen SB, Lawrence L, Ho CC, Le JE, Libiran P, Grayson PC, Ferrada MA, Beck DB, Suarez CJ.   +9 more
europepmc   +1 more source

Rapid cutaneous remission response to tofacitinib and systemic corticosteroids in VEXAS syndrome with a novel UBA1 mutation. [PDF]

JAAD Case Rep
Wang Z, Shi H, Jiang Y.
europepmc   +1 more source

Long-term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome [PDF]

Aalbers, Anna M., Dalm, Virgil A.S.H., Raaijmakers, Marc H.G.P., Valk, Peter J.M., van Daele, Paul L.A.   +4 more
core   +2 more sources

Recurrent fever and association with severe organ involvement, mortality and treatment outcomes in VEXAS syndrome: data from the AIDA Network. [PDF]

Front Immunol
Caggiano V, Sbalchiero J, Frassi M, Crisafulli F, Cavazzana I, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Wiesik-Szewczyk E, Nowakowska-Plaza A, Sfriso P, Bindoli S, Rizzo S, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Mayrink Giardini HA, González-García A, Lopalco G, Viapiana O, Bixio R, Tufan A, Hissaria P, Beecher M, Callisto A, De Paulis A, Dagna L, Campochiaro C, Tomelleri A, Bugatti S, Milanesi A, Ruiz-Irastorza G, Soto-Peleteiro A, Piga M, Cauli A, Conti F, Cardamone C, Triggianese P, Gurnari C, Vitetta R, Prete M, Racanelli V, Talarico R, Ferro F, di Cianni F, Cuccaro MC, Mayo-Juanatey A, Renieri A, Sorrentino V, Ergun MA, Balistreri A, Frediani B, Bocchia M, Fabiani C, Cantarini L, Vitale A.   +56 more
europepmc   +1 more source

JAK Inhibitors for Treatment of VEXAS Syndrome: A Systematic Review of 186 Cases. [PDF]

Dermatol Res Pract
Bahramian S, Fazeli P, Rafati A, Demokri S, Memari H, Soheili A, Esmaeili F, Pourmehdi Ardebili M, Erfani H, Vahabi SM.   +9 more
europepmc   +1 more source